Send to

Choose Destination
World J Stem Cells. 2017 Dec 26;9(12):235-240. doi: 10.4252/wjsc.v9.i12.235.

Umbilical cord blood stem cell treatment for a patient with psoriatic arthritis.

Author information

Invitrx Therapeutics, Irvine, CA 92618, United States.
Invitrx Therapeutics, Irvine, CA 92618, United States.


Clinical and laboratory results document psoriatic arthritis in a 56-year old patient. The symptoms did not resolve with standard treatments (nonsteroidal anti-inflammatory drugs, steroids and methotrexate). TNF-alpha inhibitors (certolizumab pegol and adalimumab) were added to the treatment regime, with some adverse effects. A trial of human umbilical cord stem cell therapy was then initiated. The stem cells were enriched and concentrated from whole cord blood, by removal of erythrocytes and centrifugation. The patient received several infusions of cord blood stem cells, through intravenous and intra-articular injections. These stem cell treatments correlated with remission of symptoms (joint pain and psoriatic plaques) and normalized serologic results for the inflammatory markers C-reactive protein and erythrocyte sedimentation rate. These improvements were noted within the first thirty days post-treatment, and were sustained for more than one year. The results of this trial suggest that cord blood stem cells may have important therapeutic value for patients with psoriatic arthritis, particularly for those who cannot tolerate standard treatments.


Psoriatic arthritis; Rheumatoid arthritis; Stem cells; Umbilical cord blood stem cells

Conflict of interest statement

Conflict-of-interest statement: Authors are paid employees of Invitrx Therapeutics. Torfi H is the founder and chief executive officer.

Supplemental Content

Full text links

Icon for Baishideng Publishing Group Inc. Icon for PubMed Central
Loading ...
Support Center